Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the period of May 2021, specifically dated May 5, 2021. The Company, a foreign private issuer based in Lausanne, Switzerland, is reporting the execution of a new equity sales agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a corporate action regarding capital raising.
- Program Capacity: Up to $80,000,000 in common shares.
- Commission Rate: 3.0% of the gross sales price per share.
- Share Class: Common shares with a nominal value of CHF 0.02.
Material Changes
On May 5, 2021, AC Immune SA entered into an Open Market Sales Agreement with Jefferies LLC. This agreement replaces the Company's existing "at the market" program with the same agent. The Company retains the right to suspend the offering at any time and has no obligation to sell any shares.
Guidance, Outlook, and Risks
Use of Proceeds: The Company expects to use net proceeds from any sales for research and clinical development of current and/or additional pipeline candidates, technology platforms, working capital, capital expenditures, and general corporate purposes.
Risks and Contingencies: The filing includes standard legal disclaimers noting that representations and warranties in the agreement were made solely for the benefit of the contracting parties and may not reflect the actual state of affairs of the Company at any given time. The agreement is subject to customary indemnification provisions.
Investor Verification Checklist
- Verify the current status of the $80,000,000 "at the market" program and any shares sold to date.
- Review the full text of the Open Market Sales Agreement (Exhibit 1.1) for specific terms regarding suspension rights and pricing mechanisms.
- Confirm the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Check subsequent filings for actual sales activity under this new agreement.